MY200960A - Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury - Google Patents

Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury

Info

Publication number
MY200960A
MY200960A MYPI2019002914A MYPI2019002914A MY200960A MY 200960 A MY200960 A MY 200960A MY PI2019002914 A MYPI2019002914 A MY PI2019002914A MY PI2019002914 A MYPI2019002914 A MY PI2019002914A MY 200960 A MY200960 A MY 200960A
Authority
MY
Malaysia
Prior art keywords
heart failure
reperfusion injury
cardiac
treatments
inhibitor
Prior art date
Application number
MYPI2019002914A
Other languages
English (en)
Inventor
Salomon Narodden
Original Assignee
Salomon Narodden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salomon Narodden filed Critical Salomon Narodden
Publication of MY200960A publication Critical patent/MY200960A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
MYPI2019002914A 2016-11-24 2017-11-17 Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury MY200960A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (1)

Publication Number Publication Date
MY200960A true MY200960A (en) 2024-01-26

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019002914A MY200960A (en) 2016-11-24 2017-11-17 Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury

Country Status (16)

Country Link
US (1) US20190374623A1 (cg-RX-API-DMAC7.html)
EP (1) EP3544624B1 (cg-RX-API-DMAC7.html)
JP (1) JP7231543B2 (cg-RX-API-DMAC7.html)
KR (1) KR102678011B1 (cg-RX-API-DMAC7.html)
CN (1) CN109996558A (cg-RX-API-DMAC7.html)
AU (1) AU2017365926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044624A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017482T3 (cg-RX-API-DMAC7.html)
GB (1) GB201619861D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250664T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071244T2 (cg-RX-API-DMAC7.html)
MY (1) MY200960A (cg-RX-API-DMAC7.html)
PL (1) PL3544624T3 (cg-RX-API-DMAC7.html)
RS (1) RS66778B9 (cg-RX-API-DMAC7.html)
RU (1) RU2767445C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018096319A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118680A2 (en) * 2006-04-19 2007-10-25 Ludwig-Maximilians-Universität München Remedies for ischemia
US8455435B2 (en) 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
KR20110135411A (ko) * 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor

Also Published As

Publication number Publication date
KR20190100199A (ko) 2019-08-28
PL3544624T4 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
WO2018096319A1 (en) 2018-05-31
RU2019119110A (ru) 2020-12-24
EP3544624C0 (en) 2025-02-12
RU2019119110A3 (cg-RX-API-DMAC7.html) 2021-08-30
GB201619861D0 (en) 2017-01-11
CA3044624A1 (en) 2018-05-31
KR102678011B1 (ko) 2024-06-25
JP7231543B2 (ja) 2023-03-01
EP3544624B1 (en) 2025-02-12
RU2767445C2 (ru) 2022-03-17
HUE071244T2 (hu) 2025-07-28
EP3544624A1 (en) 2019-10-02
CN109996558A (zh) 2019-07-09
HRP20250664T1 (hr) 2025-10-24
RS66778B9 (sr) 2025-08-29
PL3544624T3 (pl) 2025-11-03
JP2020510616A (ja) 2020-04-09
AU2017365926A1 (en) 2019-07-04
ES3017482T3 (en) 2025-05-13
AU2017365926B2 (en) 2025-06-05
RS66778B1 (sr) 2025-06-30

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
PH12020500555A1 (en) Esketamine for the treatment of depression
MX2021002321A (es) Nuevos metodos.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2016009063A (es) Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
IL272957B2 (en) Sublingual epinephrine tablets
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو